[Evaluation of intra-arterial infusion chemotherapy for liver metastasis from gastric cancer].
We evaluated the result of intra-arterial infusion chemotherapy on liver metastasis from gastric cancer. Of 92 cases of metastatic liver tumor, 17 cases received intra-arterial infusion chemotherapy after primary resection. For comparison, we assigned the 17 cases to two groups according to the infused agents. One group was treated with the combination therapy of 5-FU, epirubicin and MMC (FEM group: n = 7), and another with other antineoplastic agents (non-FEM group: n = 10). In the FEM group, the response rate, 1-year survival rate and 50% survival period were 33.3%, 51.4%, 430 days, respectively, while those of the non-FEM group were 10.0%, 10.0%. 147 days. Although there was no significant difference (p = 0.0951), improvements in survival rate and survival period were observed. This implies the possibility that intra-arterial infusion chemotherapy, especially the combination therapy of FEM, is an effective treatment for liver metastasis from gastric cancer.
Hashimoto
M
M
Dept. of Surgery, Nikko Memorial Hospital.
Tsuji
Y
Y
Tomita
I
I
Kon
H
H
Sasaki
R
R
Kawata
S
S
Hamada
H
H
Katsuki
Y
Y
Yasuda
T
T
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006499:Hepatic Artery; D006801:Humans; D007261:Infusions, Intra-Arterial; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary*; D008297:Male; D016685:Mitomycin / Q000008:administration & dosage; D013274:Stomach Neoplasms / Q000473:pathology*; D015996:Survival Rate
D015251:Epirubicin; D016685:Mitomycin; D005472:Fluorouracil